Adherence to heart failure management medications following cardiac resynchronization therapy.
Adherence to heart failure management medications following cardiac resynchronization therapy. Curr Med Res Opin. 2019 Sep 19;:1 Authors: Shah BR, DerSarkissian M, Tsintzos SI, Xiao Y, May D, Lu X, Kinrich D, Davis E, Lefebvre P, Duh MS, Dasta JF Abstract OBJECTIVE: The purpose of this study is to assess the real-world impact of cardiac resynchronization therapy (CRT) on adherence to heart failure (HF) medications. METHODS: MarketScan® administrative health care claims data from 2008 to 2014 among patients with HF were used. The date of first CRT implantation served as the index date. Adherence to guideline-directed medical therapy (GDMT) classes were compared during pre- and post-index periods using proportion of days covered (PDC). Comparisons between the two periods were made using the Wilcoxon sign-rank test for continuous PDC and McNemar's test for dichotomized PDC. RESULTS: Increases in medication adherence were observed for major classes of HF GDMT medications. Specifically, adherence to angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), beta blockers (BB), and furosemide increased by 22%, 24%, 32%, and 28% (all p
A pacemaker-like device restored heart function in a group of cancer survivors — mostly women with breast cancer — who had suffered from heart failure as a result of chemotherapy, a study in the Journal of the American Medical Association (JAMA) reports.
(University of Rochester Medical Center) A pacemaker-like device restored heart function in a group of cancer survivors -- mostly women with breast cancer -- who had suffered from heart failure as a result of chemotherapy treatment, a study in the Journal of the American Medical Association (JAMA) reports.
This article includes also recently announced findings on the TRANSITION study which revealed that HFrEF therapy with ARNI might be safely initiated after an acute decompensated heart failure episode, including patients with heart failure de novo and ACEI/ARB na ïve, both hospitalised or shortly after discharge, in contrary to the PARADIGM-HF trial, where patients had to be administered a stable dose of an ACEI/ARB equivalent to enalapril 10 mg a day for at least 4 weeks before the screening.
Abstract BACKGROUND: The first European Cardiac Resynchronization Therapy (CRT) Survey, conducted in 2008-2009, showed considerable variations in guideline adherence and implantation practice. A second prospective survey (CRT Survey II) was then performed to describe contemporary clinical practice regarding CRT among 42 European countries. AIM: To compare the characteristics of French CRT recipients with the overall European population of CRT Survey II. METHODS: Demographic and procedural data from French centres recruiting all consecutive patients undergoing either de novo CRT implantation or an upgrade...
This study included 36 patients. At rest, AV intervals changed minimally with posture. With atrial pacing, AV interval immediately increased compared with sinus rhythm, with ARV slopes being 8.1 ±7.7, 8.8±13.4 and 6.8±6.5 milliseconds per beat per minute (ms/bpm) and ALV slopes being 8.2±7.7, 9.1±12.8, and 7.0±6.5 ms/bpm for supine, standing and sitting positions, respectively. As paced heart rate increased, ARV and ALV intervals increased more gradually with similar trends. Intervent ricular conduction times changed
CONCLUSIONS: Reactive ATP successfully and safely reduced AF burden, and was associated with a lower incidence of HF hospitalization in patients implanted with CRT devices. PMID: 31672258 [PubMed - as supplied by publisher]
This study investigated the clinical effect of the aCRT algorithm, especially in mildly wide QRS (120≤QRS
Heart failure (HF) is a complicated syndrome, and despite advances in medical and device-based therapies in the last three decades, the 5-year mortality of patients with HF remains around 50%.1 Increasingly, patients with HF are implanted with implantable cardioverter defibrillators or cardiac resynchronization therapy devices that possess the capability of measuring many diagnostic parameters.
An implantable neuromodulation device was approved for symptom improvement in patients with advanced heart failure who aren ’t eligible for cardiac resynchronization therapy. Heart failure is the fourth leading cause of death attributable to cardiovascular disease, affecting 5.7 million people in the United States.
Nearly one-third of heart failure (HF) patients do not respond to cardiac resynchronization therapy (CRT) despite having left bundle branch block (LBBB). The aim of the study was to investigate a novel method ...